Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2020 Archives
Dec 7, 2020 Lannett Company, Inc. (NYSE: LCI) today announced the closing of a $30 million asset-backed revolving credit facility with Wells Fargo Bank, National Association. "Completing this transaction... More |
Nov 30, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay off, in full, the remaining $42 million outstanding balance of its Term A... More |
Nov 4, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 first quarter ended September 30, 2020. "We view our fiscal 2021 first quarter net sales of $126 million as a... More |
Nov 3, 2020 --Unique Oral Formulation of Levothyroxine Expands Thyroid Deficiency Product Portfolio-- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced the launch of the authorized generic of Tirosint® (Levothyroxine Sodium Capsules USP). Lannett entered into an exclusive... More |
Oct 28, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 first quarter on Wednesday, November 4, 2020, after the market closes. Lannett... More |
Aug 26, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 fourth quarter and full year ended June 30, 2020. "For both the fiscal 2020 full year and fourth quarter, our... More |
Aug 19, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 fourth quarter and full year on Wednesday, August 26, 2020, after the market closes.... More |
Aug 17, 2020 Lannett Company, Inc. (NYSE: LCI) today announced the Notice of Proposed Settlement and Dismissal with Prejudice of Derivative Action (the "Notice"), a copy of which is attached hereto as an... More |
Aug 17, 2020 --Company Extends Distribution Term for Generic ADVAIR DISKUS®-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone... More |
Aug 3, 2020 Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.'s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and... More |
Jul 27, 2020 -- Signs Exclusive U.S. Distribution Agreement with Novitium Pharma -- Lannett Company, Inc. (NYSE: LCI) today announced that it will soon launch Levorphanol Tablets 2 mg, a partnered product. Lannett entered into an exclusive U.S. distribution agreement for... More |
Jul 23, 2020 --Second Product with Strategic Partner, Rivopharm-- Lannett Company, Inc. (NYSE: LCI) today announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the... More |
Jul 16, 2020 --Lannett to Commence Marketing on August 3, 2020-- Lannett Company, Inc. (NYSE: LCI) and Cediprof, Inc., a part of the Neolpharma Pharmaceutical Group family of companies, today said that the companies have entered into an interim exclusive supply... More |
Jul 13, 2020 Lannett Company, Inc. (NYSE: LCI) today announced a restructuring and cost savings plan. The initiatives include consolidating the research and development (R&D) function into a single location in... More |
Jun 11, 2020 --Company Anticipates Biosimilar Application to be Submitted By End of Calendar Year 2022-- Lannett Company, Inc. (NYSE: LCI) today said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration (FDA) on the clinical advancement... More |
May 6, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 third quarter ended March 31, 2020. "I am incredibly proud of the effort and dedication of all of our... More |
Apr 29, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 third quarter on Wednesday, May 6, 2020, after the market closes. Lannett management... More |
Apr 8, 2020 Lannett To Meet With FDA Regarding The Clinical Advancement Of Biosimilar Insulin Glargine On June 9 Lannett Company, Inc. (NYSE: LCI) today announced that it is set to meet with the U.S. Food and Drug Administration (FDA) on June 9, 2020 to plan next steps for the clinical advancement of its... More |
Apr 7, 2020 Lannett in the News – Philadelphia Business Journal, April 7, 2020 More |
Mar 31, 2020 --Company Has Launched Five Products in Last Three Months-- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine capsule product... More |
Mar 9, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 32nd Annual ROTH Conference on March 16, 2020 at 2:30 p.m. PT at The Ritz Carlton, in Laguna Niguel,... More |
Feb 5, 2020 Financial and Business Highlights: Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2020 second quarter ended December 31, 2019. "For our fiscal 2020 second quarter, strong sales across multiple... More |
Jan 30, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2020 second quarter on Wednesday, February 5, 2020, after the market closes. Lannett... More |
Jan 13, 2020 --Company to Commence Commercial Launch Shortly, Under Brand Name NUMBRINO®-- Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA), submitted under the 505(b)(2) regulatory pathway,... More |
Jan 6, 2020 Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%. The... More |